Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azer-cel in B-cell Mediated Autoimmune Disorders
NCT06680037Phase 1Recruiting
- Sponsor
- TG Therapeutics, Inc.
- Start
- May 2025
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azercabtagene zapreleucel in multiple sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), myasthenia gravis (MG) and 2 more, sponsored by TG Therapeutics, Inc. Primary endpoint: Dose-Limiting Toxicities. Started May 2025; status: recruiting.
02
Drugs
azercabtagene zapreleucel
03
Conditions
multiple sclerosis (MS)Neuromyelitis Optica Spectrum Disorder (NMOSD)myasthenia gravis (MG)chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)autoimmune nodopathy (AN)
Beyond the preview
Go deeper on NCT06680037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06680037.